Crohn disease and ulcerative colitis comprise the 2 primary subtypes of inflammatory bowel diseases (IBD). IBD currently has no known cure and whose pathogenesis is not well understood. However, an increasing amount of research points to genetic risk factors combined with antibiotic use and changes in intestinal microbiota as triggers for the onset of IBD.1,2…
Researchers evaluated the efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders, in patients with moderate to severe ulcerative colitis.
In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.
As frailty has been linked to outcomes in patients with other inflammatory diseases, the researchers examined the relationship between frailty and the risk for infections after immunosuppression for inflammatory bowel disease.
Ileal pouch–anal anastomosis surgery as treatment for ulcerative colitis met the expectations of cure of the disease, maintaining adequate long-term intestinal functionality associated with a good quality of life.
Prospective studies are needed to validate the Ulcerative Colitis Response Index algorithm as a surrogate marker panel for mucosal healing, with the ultimate goal being to avoid unnecessary endoscopic evaluations.
An inflammatory bowel disease diagnosis conferred an increased risk for venous thromboembolism; however, in surgical patients, ulcerative colitis but not Crohn disease was responsible for the elevated risk.